First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Aptevo Therapeutics Inc. (APVO): the developments shaping its investment case

    Follow the evidence affecting Aptevo Therapeutics Inc.'s valuation assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Aptevo Therapeutics Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-03
    Aptevo Therapeutics Reports 93% Clinical Benefit Rate with Mipletamig Triplet in AML
    Channel: Direct positive clinical trial results for lead candidate, increasing probability of regulatory approval and future commercialization.
    Bullish· 1-3m
    2026-08-14 · 2 reports
    Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc.
    Channel: Direct equity investment provides capital; strategic collaboration offers potential for new revenue streams and pipeline development.
    Bullish· 1-3m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-08-14multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.
    2026-08-14share_countBullishPrimary equity issuance increases diluted share count.

    Event impact log

    3 events mapped to APVO since 2026-08-14. Evidence through 2026-09-03.

    DateEventChannelDirectionHorizonImpact
    2026-09-03Aptevo Therapeutics Reports 93% Clinical Benefit Rate with Mipletamig Triplet in AMLDirect positive clinical trial results for lead candidate, increasing probability of regulatory approval and future commercialization.Bullish1-3m0.90
    2026-08-14Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc.Direct equity investment provides capital; strategic collaboration offers potential for new revenue streams and pipeline development.Bullish1-3m0.70
    2026-08-14Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc.Dilution from equity issuance; long-term success of collaboration is uncertain.mixed1-5y0.40

    Continue this research

    Build your Aptevo Therapeutics Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the APVO entity page →

    Research Aptevo Therapeutics Inc. · $399/mo